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The 2010 Annual Meeting of the International Society for Stem Cell Research (ISSCR) was held in
San Francisco in June with an exciting program covering a wealth of stem cell research from basic science
to clinical research.Nearly 4000 scientists from 49 countries filled the vast audito-
rium of Moscone West in San Francisco for the opening session
of the 8th Annual Meeting of the ISSCR. The stellar science
presented in 8 plenaries and 15 concurrent sessions by 108
speakers over the ensuing four days led many to conclude that
this was the best ISSCR annual meeting to date.
As promises of new stem cell therapies move closer to reality,
ISSCR President Irving Weissman opened the meeting reiter-
ating the society’s commitment to champion the responsible
clinical translation of stem cell research and highlighting the
ISSCR’s recent initiative that resulted in the June 2010 launch
of a new public education resource, A Closer Look at Stem
Cell Treatments (www.closerlookatstemcells.org).
In his Keynote Address on neuronal plasticity and diversity,
Fred Gage (Salk Institute, USA) led off with a beautiful review
of neurogenesis in the adult brain and then focused on the role
of long interspersed nuclear element (LINE-1) retrotransposons
in modulating gene expression in developing neurons (Singer
et al., 2010). Although LINE-1 elements constitute nearly 20%
of the mammalian genome, most are truncated copies that are
fixed in position. In fact, in the human genome there are approx-
imately 150 full-length potentially mobile LINE-1 elements, and
probably only a handful of these are responsible for most
retrotransposition activity. New LINE-1 insertions occur pre-
dominantly in developing neural cells, both during embryonic
neurogenesis and in the adult brain. It is believed that LINE-1
activation, regulated by the Wnt signaling pathway, can affect
gene expression and thus cellular phenotype. Gage maintains
that LINE-1 induced somaticmosaicismmay ultimately influence
cognition and behavior—adding a whole new interpretation to
the notion of ‘‘changing your mind’’!
The winner of the 2010 ISSCROutstanding Young Investigator
Award, Joanna Wysocka (Stanford University, USA), also dis-
cussed developmental plasticity, examining how epigenetic pro-
cesses influence gene expression in the neural crest. Mutations
in the gene encoding chromodomain helicase DNA-binding
domain (CHD)7 cause a complex disorder with prominent
craniofacial malformations, termed CHARGE syndrome. In order
to confirm the long-standing hypothesis that CHARGE syndromerepresented a neural crest disorder, Wysocka’s laboratory
established an in vitro model of neural crest-like cell (hNCLC)
formation from hESCs and demonstrated that hNCLCs ex-
pressed high levels of CHD7. She showed that siRNA-mediated
downregulation of this gene perturbed cell migration and
reduced the transcription of genes specifying neural crest
migration and specification. Recently, her laboratory discovered
the association of CHD7 with another chromatin remodelling
protein, PBAF (polybromo- and BRG1-associated factor con-
taining complex) (Bajpai et al., 2010). This research has broad
implications, providing an example for the synergistic control
of distal enhancers by complexes of chromatin remodeling
proteins.
This year, the Anne McLaren Memorial Lecture was delivered
by Brigid Hogan (Duke University, USA), who discussed epithe-
lial stem and progenitor cells in lung development, homeostasis,
and repair—a timely topic given that 2010 is the Year of the Lung.
Highlighting important differences in size and structure between
mouse and human lung, Hogan pointed out that undifferentiated
basal cells, which express the transcription factor Trp-63 (p63)
and cytokeratins 5 (Krt5) and 14 (Krt14), are restricted to the
trachea in mice but are found throughout the small airways in
the human lung. Lineage-tracing studies in the mouse demon-
strated that tracheal basal cells gave rise to ciliated and secre-
tory cells and that viable basal cells could be isolated from
tracheal epithelium by virtue of their expression of the nerve
growth factor receptor (Ngfr, p75). Growth in a clonogenic assay
in vitro revealed that basal cells could renew and differentiate in
the absence of stroma. Translation of this work to human lung
epithelium revealed similar clonogenic properties in human
lung basal cells purified on the basis of their combined expres-
sion of NGFR and ITGA6 (Rock et al., 2009). Currently, her
laboratory is dissecting the pathways that bias basal cell differ-
entiation toward either secretory or ciliated epithelium.
Toward Cell Therapies—Work in Progress
A session devoted to cell therapy opened with an update of the
much-publicized clinical trial to evaluate the role of human
embryonic stem cell (hESC)-derived oligodendrocytes in theCell Stem Cell 7, 443–450, October 8, 2010 ª2010 ISSCR 443
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(Geron Corporation, USA) explained that stored oligodendro-
cytes will be injected into the spinal cord lesion in patients within
2 weeks of injury. On the basis of preclinical studies in rats, it is
hypothesized that the oligodendrocytes might have a beneficial
effect by restoring the damaged myelin sheath around nerve
bundles. The trial was temporarily put on hold after the identifica-
tion of microscopic epithelial cysts in the spinal cord of some
recipient rats. It appears that these were benign, composed of
endothelial cells, allowing the clinical hold to be lifted on July
30, 2010 and the trial to proceed.
Despite significant advances in the generation of cardiomyo-
cytes from human pluripotent stem cells, several speakers
indicated that using these cells for therapy still seemed remote.
Joseph Gold, Gordon Keller (McEwen Centre for Regenerative
Medicine, Canada), Kenneth Chien (Massachusetts General
Hospital, USA) and Christine Mummery (Leiden University
Medical Center, Netherlands) described high yields of cardio-
myocytes from hESC and human induced pluripotent stem cells
(hiPSCs), with cultures under defined growth factor conditions
reproducibly generating over 50% cardiomyocytes. Although
the spectacular beating sheets of immature cells should be
well-suited to transplantation, there remained significant addi-
tional hurdles to overcome. In addition to hazards posed by
xenoreagents, residual undifferentiated pluripotent cells and
immune rejection, cardiac cell transplantation presents risks of
inducing arrhythmias and difficulties in achieving proper cell
alignment. However, both Keller and Chien presented potential
tissue engineering solutions to the latter problems. Geron’s car-
diomyocyte studies are now being extended to the guinea pig
and pig—larger animal models in which it would be easier to
detect adverse effects and to meet challenges related to cell
preparation, administration, and safety associated with the
larger cell doses required for human cell therapy.
In addition to improving the efficiency of stem cell differentia-
tion, for many applications it would also be useful to identify
cell-surface markers that could be used to enrich for viable
progenitors or differentiated cells. Ali Nsair (University of Califor-
nia, Los Angeles, USA) proposed that tripotent cardiac progen-
itors expressing the transcription factor Isl1, usually identified444 Cell Stem Cell 7, 443–450, October 8, 2010 ª2010 ISSCRby expression of the VEGF2-receptor flk1, could be more readily
identified with a combination of antibodies directed against
the tyrosine kinase receptors flt1 and flt4. Cells selected from
differentiating hESCs, hiPSCs, and human fetal heart with this
strategy were enriched for cardiomyocyte, endothelial, and
smooth muscle differentiation potential.
Diseases affecting the skin and the cornea have also been
targeted for stem cell therapies. Daniel Miller (University of
Washington, USA) presented a combined cell (keratinocyte)
and gene therapy approach to a severe blistering skin disease,
epidermolysis bullosa simplex, caused by a dominantly inherited
mutation in KRT5 or KRT14. Miller used an adeno-associated
virus vector to target and repair the mutation in human keratino-
cytes and showed that these genetically repaired cells, grown on
a matrix scaffold, organized into a normal skin epithelium, which
could be successfully grafted to athymic mice (Petek et al.,
2010).
Impressive progress in stem cell therapy has also been made
for some eye diseases. Graziella Pellegrini (University of Modena
and Reggio Emilia, Italy) described the use of stem cells from the
corneal limbus in the treatment of corneal disease. Limbal stem
cells cultured from the contralateral healthy eye were expanded
in vitro and transplanted to repair the damaged cornea. Long-
term follow-up revealed that successful ongoing corneal regen-
eration was dependent upon the frequency of high proliferative
potential, p63-expressing ‘‘holoclones’’ within the transplanted
population (Rama et al., 2010). This avenue of research is partic-
ularly promising because there are options to use either autolo-
gous or allogeneic limbal stem cells, given that the cornea is not
sensitive to immune rejection.
Alexandra Capela, from StemCells, Inc., USA, discussed the
use of human fetal central nervous system stem (hCNS-SCns)
cells for the treatment of age related macular degeneration.
hCNS-SCns cells have been shown to be neuroprotective in
a mouse model of infantile neuronal ceroid lipofuscinosis (Tam-
aki et al., 2009) and are now under evaluation for the treatment
of fatal neurodegenerative disorders in children. Capela argued
that retinal degenerative diseases might similarly benefit from
neuroprotective strategies to reduce photoreceptor loss. In
rats predisposed to postnatal retinal degeneration, injection of
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maintained near-normal visual acuity. The opportunity to test
this therapy in humans is eagerly awaited since hCNS-SCns cells
have already been banked for use in clinical trials for neurode-
generative diseases.
The generation of human pancreatic beta cells as cell therapy
for type 1 diabetes is an area of intense research interest for
groups around the world. Kevin D’Amour (ViaCyte, Inc., USA;
formerly Novocell, Inc.) described their recent progress in the
differentiation of hESCs to pancreatic progenitors. Previously,
they published that hESCs differentiated to pancreatic endo-
derm reversed type 1 diabetes in a mouse model following a
3 month in vivo maturation stage (Kroon et al., 2008). D’Amour
described hESC differentiation in cellular aggregates, rather
than as a monolayer, in order to enable upscaling to the cell
numbers required for clinical use. The differentiated product
was high in purity for pancreatic precursors, could be cryopre-
served, and differentiated efficiently in vivo to yield structures
that were very similar to pancreatic islets. D’Amour also
described an encapsulation device that would address issues
of patient safety, by simultaneously protecting the graft from
immunological attack and blocking egress of any unwanted
proliferating cells, while still enabling graft endocrine function.
Metabolism and Stress Response
Two plenary sessions were devoted to metabolic regulation and
stress response in stem cells, which attested to the strong
interest in basic stem cell biology. Celeste Simon (University of
Pennsylvania, USA) described her ongoing work on oxygen
deprivation and hypoxia-inducible factors (HIFs) in stem cells
and cancer. The HIFs and their interacting partner, ARNT, modu-
late several essential stem cell effector pathways, including
Notch,Wnt/b-catenin, and Oct4 that influence stem cell prolifer-
ation, differentiation and pluripotency in low oxygen concentra-
tions. She highlighted the importance of these regulatory
mechanisms for neuronal and hematopoietic stem cell (HSC)
maintenance in their respective hypoxic niches. Ricardo Pardal
(Instituto de Biomedicina de Sevilla, Spain) described hypoxia-
induced postnatal neurogenesis in the carotid body, the organ
detecting oxygen tension in the arterial blood, through changes
in the ratio of quiescent and proliferative glial-like stem cells.
Marc Van Gilst (Fred Hutchinson Cancer Research Center,
USA) and Yukiko Yamashita (University of Michigan, USA)
showed that nutrient availability regulates stem cell numbers
and overall tissue architecture. Using the nematode, C. elegans,
Van Gilst illustrated that regulation of fat expenditure and lipid
synthesis controlled the biological activity of germline stem cells
and the reproductive status of the worm through the NHR49
pathway (Angelo and Van Gilst, 2009). Yamashita explained
that nutrients provided to the fruit fly D. melanogaster impacted
on centrosome orientation and dictated the rate of cell division in
the male germline stem cells through the insulin pathway.
Pier Giuseppe Pelicci (University of Milan, Italy) delivered the
first in a series of talks describing the DNA damage response
of several stem cell populations that highlighted the prominent
roles and contrasting functions of the p53 and p21 tumor
suppressor genes (Cicalese et al., 2009; Viale et al., 2009). Using
X-rays to illustrate genotoxic stress, he discussed the impor-
tance of the cell cycle inhibitor p21 in maintaining the stem cellpool in normal and malignant HSCs and mammary stem cells.
Lenhard Rudolph (Ulm University, Germany) discussed the
ameliorating effects of p21 deletion on the shortened lifespan
of telomere dysfunctional mice and expanded on the role of
p53-induced senescence and apoptosis as a response to telo-
mere dysfunction. p53 played a unique role in protecting adult
stem cells against the accumulation of mutations with conse-
quences for aging and cancer development (Begus-Nahrmann
et al., 2009). Emmanuelle Passegue´ (University of California,
San Francisco, USA) showed that enhanced prosurvival gene
expression and activation of p53-mediated DNA damage
response ensured the survival of HSCs in response to ionizing
radiation. She also presented provocative data indicating that
the prevalent DNA repair mechanism active in quiescent HSCs
(nonhomologous end-joining mediated repair) is prone to gener-
ating mutations in this long-maintained self-renewing population
(Mohrin et al., 2010). Cedric Blanpain (Universite´ Libre de Brux-
elles, Belgium) reported similar findings in hair follicle bulge
stem cells (Sotiropoulou et al., 2010), which suggests that
vulnerability to mutagenesis might be a general property of
quiescent stem cell populations either normal or cancerous.
Craig Jordan (University of Rochester, USA) postulated that
killing cancer stem cells requires combinatorial drug therapies
that will more effectively kill all tumor cells by inhibiting develop-
mental pathways and antagonizing protective mechanisms that
are active in stem and progenitor cells. As examples of the
cancer stem cell targets that new therapies might address, he
listed induction of oxidative stress linked with concomitant
inhibition of the NFkB-mediated survival pathway, the redox
balancing system, heat-shock proteins, and anti-oxidant protec-
tive mechanisms.
Refining Reprogramming
The intense interest in cellular reprogramming since the initial
presentation of iPSCs at the 4th ISSCR Annual Meeting in 2006
continued during this meeting. Shinya Yamanaka (Kyoto Univer-
sity, Japan and Gladstone Institutes, USA) discussed the
requirement for Myc genes in reprogramming somatic cells to
pluripotency. He concluded that c-Myc increased the frequency
of iPSC generation but that this was associated with reactivation
of the c-Myc virus and tumor formation in mice generated with
these cells. However, Yamanaka reported reprogramming
fibroblasts by using a cocktail of factors inwhich L-Myc, aweakly
transforming family member of the Myc family, was substituted
for c-Myc. The inclusion of L-Myc led tomore efficient generation
of iPSC clones that infrequently led to tumors in chimeric mice
(Nakagawa et al., 2010).
Work by several laboratories employed different approaches
to compare ESCs and iPSCs. George Daley (Children’s Hospital
Boston, USA) described global DNA methylation analysis that
revealed a significant number of differentially methylated regions
between ESCs and iPSCs, consistent with the concept that
iPSCs retain an ‘‘epigenetic memory’’ that reflected their cell
type of origin. Perhaps as a consequence of these epigenetic
differences, Daley noted that iPSCs tended to differentiate
more efficiently toward cell types related to their cell of origin
(Kim et al., 2010). In an elegant series of studies, Konrad Ho-
chedlinger (Massachusetts General Hospital, USA) profiled
genetically matched mouse iPSCs that differed in their capacityCell Stem Cell 7, 443–450, October 8, 2010 ª2010 ISSCR 445
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tetraploid complementation. Surprisingly, he uncovered a
single locus on chromosome 12, containing a few mRNAs and
microRNAs (miRNAs), whose expression correlated with the
developmental potential (Stadtfeld et al., 2010). In most iPSC
clones the locus was silenced, and the iPSCs produced low
contribution chimeras. In rare iPSC clones in which the locus
was expressed, the cells made high contribution chimeras and
even all-iPSC mice. Treatment of the silenced clones with a
histone deacetylase inhibitor reactivated expression from the
locus and induced full developmental potential to the iPSCs.
Christa Buecker (Massachusetts General Hospital, USA) con-
trasted the distinct leukemia inhibitory factor (LIF)-dependent
ESC and fibroblast growth factor (FGF)-dependent epiblast
stem cell (EpiSCs) ‘‘states’’ that can be reversibly adopted by
mouse pluripotent cells. Human ESCs more closely resemble
mouse EpiSCs in their growth rates, factor requirements, and
reluctance to passage as single cells. To derive human cell lines
that were more similar to mESCs and therefore more amenable
to genetic modification, Buecker and colleagues introduced
inducible reprogramming factors into human fibroblasts that
they cultured in the presence of LIF to derive colonies of cells
(denoted hLR5 cells) that morphologically and immunopheno-
typically resembled mESCs (Buecker et al., 2010). Interestingly,
levels of endogenousOCT4,NANOG, SOX2, andMYC remained
low in hLR5 cells and they remained dependent upon the expres-
sion of exogenous reprogramming factors. However, Buecker
observed that the hLR5 cells displayed a similar facility for
genetic modification to mESCs, generating over 100-fold more
stable transfectants than an equivalent number of hESCs.
Direct Fate Conversion
The ability of pigmented retinal epithelium in the chick to develop
into lens cells was observed over 30 years ago, and this switch
in cellular differentiation was termed ‘‘transdifferentiation’’
(Eguchi and Kodama, 1993). In this case, it was clear that the
cells ‘‘dedifferentiated’’ to a stem or progenitor cell state first.
Infrequently, the mis-expression of a single gene can convert
one cell type into another, without apparent dedifferentiation,
as was the case for muscle switching of C3H10T1/2 fibroblasts
by MyoD (Davis et al., 1987). The advent of somatic cell reprog-
ramming fueled renewed interest in direct cellular fate conver-
sion using multiple genes, thus circumventing a pluripotent
intermediate. Following on the heels of the successful conver-
sion of adult pancreatic exocrine cells to beta cells in vivo re-
ported by Douglas Melton (Harvard University, USA) at the
ISSCR 6th Annual Meeting in Philadelphia, several speakers
presented the results of direct reprogramming studies.
Marius Wernig (Stanford University, USA) described experi-
ments that aimed to generate neural lineages in a single step.
He transduced murine fibroblasts with a combination of 19
candidate genes and eventually identified three factors that effi-
ciently reprogrammed fibroblasts to induced neural cells, with a
predominantly excitatory cortical neuron phenotype (Vierbuchen
et al., 2010). It remains to be seen whether the reprogramming
factors can be dispensed with and how readily neurons of
different subtypes can be produced. Kevin Eggan (Harvard
University, USA) explored the reprogramming of fibroblasts
directly to motor neurons, with a view to developing new treat-446 Cell Stem Cell 7, 443–450, October 8, 2010 ª2010 ISSCRments for amyotrophic lateral sclerosis. He reprogrammed fibro-
blasts harboring a motor neuron-specific GFP reporter with
various combinations of factors. Success eluded him, however,
until he also added the three factors used by Wernig. In the final
talk on this theme, Deepak Srivastava (Gladstone Institutes,
USA) discussed the reprogramming of cardiac-derived ‘‘fibro-
blasts’’ to cardiomyocytes (Ieda et al., 2010). He used a combina-
tion of 14 transcription factors to reprogram the fibroblasts to a
cardiac fate. Srivastava refined the list of reprogramming genes,
leading to the conclusion that a three factor combination would
successfully reprogram fibroblasts to beating, electrically active
cells with a phenotype similar to ventricular cardiomyocytes.
Importantly, using a lineage tracing strategy, his group showed
that the fibroblasts were directly induced into cardiomyocytes,
bypassing a progenitor intermediate.
Germ Cells, Imprinting and Reprogramming
Primordial germ cells (PGCs) hold a unique place in the stem cell
hierarchy given that it is these cells that give rise to gametes and
represent a literal genetic link to the next generation. Several
talks were related to the biology of PGCs derived frommammals
and nonvertebrate species. Crucial to PGC formation in females
is the reactivation of the somatically silenced X chromosome as
the PGCs migrate to the urogenital ridge. Kathrin Plath (Univer-
sity of California, Los Angeles, USA) pointed out that, unlike
female mESCs, most female hESC lines carry one inactive X
chromosome. Recent work from the group of Jaenisch and
Mitalipova showed that this may be due to oxidative stress and
that female hESCs derived under 5%oxygen conditions retained
two active X chromosomes that were randomly inactivated upon
further differentiation (Lengner et al., 2010). Interestingly, Plath
showed that, like the hESCs, hiPSCs had only one active X
chromosome. However, unlike the derivation of hESCs, reprog-
ramming under hypoxic conditions did not support X reactivation
(Tchieu et al., 2010). Plath made the important observation that
because the inactivated X is retained during reprogramming
and differentiation, iPSC clones were well positioned for the
study of X-linked diseases (such as Duchenne Muscular
Dystrophy) because it would be possible to get clonal lines either
expressing the wild-type or mutant allele from the same female
patient.
Studies in nonvertebrate species reported examples of gene
mutations affecting germ cell development that also affect hu-
mans. As an example, Shuyi Chen (Stowers Institute for Medical
Research, USA) discussed the role of Lis1, which is required
for maintaining BMP signaling and the balance between self-
renewal and differentiation in Drosophila germ cells. A further
highlight was the presentation by Mitinori Saitou (RIKEN Center
for Developmental Biology, Japan), who studied germ cell spec-
ification in mice and the role of the transcription factors Blimp1
(Prdm1) and Prdm14, which are coexpressed in the PGCs (Ohi-
nata et al., 2009). Saitou showed that extraembryonic signals
were key regulators of germ cell induction. Under defined culture
conditions, in the presence of BMP4, most of the isolated
epiblast cells in wild-type mouse embryos became Blimp1-
and alkaline phosphatase-positive PGCs. These culture-
induced PGCs developed into sperm upon injection into the
testes of aspermic mice and gave rise to viable offspring. Similar
signaling pathways appear to be active in mESCs and data
Cell Stem Cell
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were similar whether the PGCs were derived from the epiblast or
ESCs.
MicroRNA Regulation of Stem Cells
Robert Blelloch (University of California, San Francisco, USA)
discussed the roles for miRNAs in regulating the switch between
self-renewal and differentiation in embryonic stem cells (Melton
et al., 2010). Blelloch’s laboratory discovered antagonistic roles
for two families of miRNAs, the ESCC and let-7 miRNAs, which
are highly expressed in ESCs and differentiated tissues, respec-
tively. The ESCC miRNAs enhance self-renewal of ESCs and
promote the dedifferentiation of somatic cells to iPSCs. In
contrast, the let-7 miRNAs promote the differentiation of ESCs
and inhibit the dedifferentiation of somatic cells to iPSCs. He
also discussed surprising findings that all miRNA function is sup-
pressed in oocytes and preimplantation embryos, postulating
that this may be essential for the massive reprogramming that
occurs in the early embryo (Suh et al., 2010).
Narry Kim (Seoul National University, Republic of Korea) pre-
sented elegant work from her laboratory on the posttranscrip-
tional regulation of let-7 (Heo et al., 2009). Like all canonical
miRNAs, let-7 is transcribed as a long pri-miRNA. The pri-miRNA
is processed first by an RNase, Drosha, to a pre-miRNA and then
by another RNase, Dicer, to a mature miRNA. Kim and others
have shown that the RNA binding protein Lin28 and the terminal
uridylase Tut4 regulate the biogenesis of let-7. Lin28 is highly
expressed in ESCs and together with Tut4 adds uridines at the
end of the let-7 pre-miRNA, destabilizing and inhibiting its further
processing by Dicer in ESCs. In contrast, Lin28 expression is
reduced upon differentiation resulting in increased levels of
mature let-7.
Using an inducible overexpression system, Hao Zhu (Chil-
dren’s Hospital Boston, USA) examined the role of Lin28
in vivo in the mouse (Zhu et al., 2010). Induction of Lin28 resulted
in a rapid expansion of the intestinal progenitor cell pool, consis-
tent with a block in differentiation and increased proliferation.
Interestingly, leaky expression of the Lin28 transgene led to an
increase in size of most organs in the mouse, consistent with
the postulated role for let-7 in suppressing stem cell self-renewal
and proliferation.
Leanne Jones (Salk Institute, USA) also discussed the impor-
tance of let-7 in stem cell regulation in the Drosophila germline.
Her laboratory has studied the molecular mechanisms respon-
sible for the decreasing number of male germline stem cells as
the fruit fly ages. The JAK-STAT signaling ligand Upd, which is
expressed by the niche (hub) cells, is essential for maintaining
the germline stem cells and its expression decreases with age.
In recent studies she has observed that let-7 expression
increases in the hub cells with age, and such an increase
indirectly results in the loss of Upd.
Of course, there are other important miRNAs in addition to
let-7. Xinyu Zhao (University of New Mexico, USA) showed that
the epigenetic regulator MBD1 controls a miRNA, miR-184, to
regulate neural stem cell (NSC) proliferation and differentiation
(Liu et al., 2010). Zhao’s laboratory found that MBD1 binds the
miR-184 promoter and inhibits its expression. miR-184 itself
promotes proliferation and inhibits differentiation of NSCs, at
least in part by regulating the importantNSC regulatorNumb-like.Small-Molecule Screening for Stem Cell Regulation
The variety of talks concerned with screens for molecules
affecting stem cell behavior or influencing differentiation re-
flected the importance of small molecules as replacements for
recombinant growth factors and as treatments for disease in
their own right. Leonard Zon (Children’s Hospital Boston, USA)
described the results of two recent small-molecule screens in
zebrafish. In the first screen, his laboratory identified two small
molecules that suppressed growth of rhabdomyosarcomas
induced by a mutant Ras (G12V) oncogene. Both molecules
targeted signaling proteins downstream of the Ras pathway
and displayed synergy when used in combination. In the second
screen, they examined a B-raf (V600E):p53/melanomamodel,
in which neural crest stem cell genes, including crestin, were
highly expressed. Zon’s laboratory screened for molecules that
would block crestin expression, identifying a small-molecule
inhibitor of the enzyme dihydrooratate dehydrogenase. Inhibition
of this enzyme depleted the ribonucleotide pool and, therefore,
would be hypothesized to inhibit transcriptional elongation.
Indeed, administration of the dihydrooratate dehydrogenase
inhibitor phenocopied deletion of the RNA polymerase associ-
ated factor, spt5, a known regulator of transcriptional elongation.
Rodolfo Gonzalez (The Scripps Research Institute, USA)
described the development of a library of extracellular and
single-pass transmembrane proteins and their use in a pluripo-
tency screen (Gonzalez et al., 2010). Open reading frames en-
coding these proteins were subcloned, purified, and screened
for their ability to maintain OCT4 expression in hESCs cultured
in the absence of bFGF. In addition to bFGF itself, they identified
another protein ligand, pigment epithelium derived growth factor
(PEDF) that maintained hESC marker expression, pluripotency,
and chromosomal stability. They are extending their screens to
identify molecules that influence hESC differentiation.
Shuibing Chen (Harvard University, USA) discussed the results
of small-molecule screens aiming to identify promoters of endo-
derm lineage differentiation, with the ultimate goal of producing
insulin-producing beta cells. She reviewed the results of the
screen that led to the identification of indolactam V (an activator
of protein kinase C) as an inducer of differentiation of gut
endoderm to PDX1+ pancreatic endoderm (Chen et al., 2009).
She has recently been focusing on the next step in differentia-
tion, from PDX1+ pancreatic endoderm to NGN3+ endocrine
cells. At this stage Chen suggests that there are a couple of
promising candidate molecules that not only increase the num-
ber ofNGN3+ cells but also the number of cell clusters containing
C-peptide+ Glucagon endocrine cells, consistent with beta cell
differentiation.
Justin Ichida (Harvard University, USA) discussed efforts to
discover small-molecule replacements for reprogramming
genes inmouse iPSC generation. He described a small-molecule
inhibitor of TGF-b, which can replace Sox2 by activating Nanog
(Ichida et al., 2009). He indicated that a small-molecule replace-
ment for KLF4 had been found, which like the Sox2 replacer,
acted late in reprogramming.
Sheng Ding (The Scripps Research Institute, USA) focused
on small molecules that promote hESC survival in culture (Xu
et al., 2010). His laboratory identified two small molecules, thia-
zovivin and pyrintegrin, that enhance hESC colony formation
following enzymatic dissociation and replating on matrigel.Cell Stem Cell 7, 443–450, October 8, 2010 ª2010 ISSCR 447
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sion-mediated integrin signaling, synergizing with growth factors
to enhance survival. In addition, thiazovivin enhanced hESC
survival in suspension culture, acting to stabilize E-cadherin
and directly inhibiting Rho-associated kinase (ROCK).
Stem Cell Niche and Hematopoiesis
In the skin, there are at least three independent stem cell popu-
lations—in the bulge of the hair follicle, the sebaceous gland,
and the basal layer of the interfollicular skin. They self-renew,
differentiate, and have long-term proliferative potential, but differ
in their cell cycle status, explained Elaine Fuchs (Rockefeller
University, USA). The bulge cells remain largely quiescent,
whereas the other stem cell populations proliferate. The quies-
cent bulge cells are recruited back into cycle after damage and
during regular hair growth cycles. The Fuchs laboratory is
studying the signaling pathways that regulate the recruitment
of bulge stem cells into the transit amplifying cell compartment
and the source of that signal within the niche. Wnt and BMP
are among the candidate signaling pathways under investiga-
tion. Furthermore, they are studying the misregulation of
these pathways in skin cancers. To this end, they have recently
developed a novel in vivo screening approach in mouse skin
by injecting viruses in utero, which efficiently transduce the
embryonic skin and thus will enable large-scale gene knock-
down screens (Beronja et al., 2010).
Valerie Horsley (Yale University, USA) focused on the regula-
tory role of the hair follicle niche, specifically investigating the
part that adipocytes play in regulating the hair follicle growth
cycle building on the exciting finding that BMPs released by
dermal adipocytes regulate the hair cycle (Plikus et al., 2008).
The Horsley laboratory has been delving deeper into the nature
of the adipocytes, including their cell cycle dynamics during
the hair cycle and the relative importance of progenitor versus
mature adipocytes in the process.
The role of integrin-ECM interactions in regulating the
asymmetric divisions of intestinal stem cells in Drosophila was
discussed by Ryan Conder (Institute of Molecular Biotech-
nology, Austria). Knockdown of the Drosophila integrin mew
increased stem cell number and was associated with mislocali-
zation of the Par protein, aPKC, loss of spindle polarity, and
loss of asymmetry of expression of the Numb protein. These
latter findings are reminiscent of findings in the neuroblast
lineage suggesting common mechanisms of asymmetric cell
divisions across somatic lineages.
Mark LaBarge (Lawrence Berkeley National Laboratory, USA)
discussed the effect of E-cadherin expression levels on cellular
organization within mammary tissue. He showed that the mixing
of luminal and myoepithelial cells leads to reorganization into
ductal structures that is dependent on E-cadherin signaling
pathways. Myoepithelial cells express low, luminal cells express
intermediate, and progenitors cells express high levels of
E-cadherin.
Shahin Rafii (Weill Cornell Medical College, USA) described
recent work studying the interplay between endothelial cells
(ECs) and HSCs (Butler et al., 2010). With a human umbilical
vein endothelial cell coculture system, mouse HSCs could be
expanded in vitro, maintaining stem cell marker expression
and functional capacity in transplant assays. Similarly, human448 Cell Stem Cell 7, 443–450, October 8, 2010 ª2010 ISSCRHSCs could be expanded while still retaining the ability to repo-
pulate NOD-SCID mice. A search for potential factors provided
by the ECs uncovered expression of Notch ligands, whose
significance was confirmed by the concomitant activation of a
transgenic Notch reporter in the cocultured HSCs. In vivo,Notch
ligands are provided by the bone marrow sinusoidal endothelial
cells. Inhibition of sinusoidal formation with anti-VEGFR2 and
anti-VE-cadherin antibodies inhibited Notch activation and
long-term HSC expansion in coculture. Rafii’s laboratory is
now searching for additional pathways important in this critical
interaction between ECs and HSCs. These findings hold great
promise for clinical expansion of HSCs in vitro.
David Scadden (Massachusetts General Hospital, USA)
described how microenvironmental deregulations in the bone
marrow niche impacted on hematopoiesis and contributed to
hematological disorders. He presented the recent finding from
his laboratory that inactivation of the miRNA processing gene
Dicer in osteoblastic progenitors led to a myelodysplastic syn-
drome that could be relevant to the pathogenesis of Schwach-
man-Bodian-Diamond syndrome, a human bone marrow failure
and leukemia predisposition condition (Raaijmakers et al., 2010).
The role of the ets family gene Erg in hematopoiesis and
myeloproliferative disease was discussed by Benjamin Kile
(The Walter and Eliza Hall Institute of Medical Research,
Australia). Kile’s group showed that Erg was required for defini-
tive hematopoiesis, adult hematopoietic stem cell function, and
the maintenance of normal peripheral blood platelet numbers
(Loughran et al., 2008). They are now examining the role that
ERG may play in the myeloproliferative disease and acute
leukemia associated with Down’s syndrome—a tantalizing
prospect, given that ERG lies in the minimal trisomic region of
chromosome 21.
Stem Cells of the Digestive Tract
The characterization of stem cells of the intestinal epithelium,
marked by their expression of the orphan G-coupled receptor
Lgr5, was discussed by Hans Clevers (Hubrecht Institute,
Netherlands). Clevers demonstrated that, in the mouse, cells
with stem cell characteristics expressed high levels of an Lgr5-
GFP transgenic reporter gene and could be expanded in vitro
to form gut-like organoids (Barker et al., 2010). Although these
structures grew in the absence of a nonepithelial stromal compo-
nent, their close association with Paneth cells and evidence of
reciprocal signaling between these two cell types suggested
that Paneth cells performed a niche-like function in the gut.
In contrast, work on Drosophila intestinal stem cells presented
by Rongwen Xi (National Institute of Biological Sciences, China)
provided evidence that muscle cells maintained the overlying
intestinal stem cells. Xi showed that ligands such as wingless
and unpaired are secreted by the muscle cells and regulate
stem cell proliferation in a paracrine fashion (Lin et al., 2008,
2010).
Also working in Drosophila, David Bilder (University of Califor-
nia, Berkeley, USA), showed that food intake could influence
intestinal stem cell self-renewal. He discovered that there is
insulin release from the muscle underlying the mid-gut epithe-
lium following feeding, immediately preceding an increase in
proliferation of the overlying stem cells. Deletion of the insulin
receptor in the stem cells blocks proliferation in response to
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results in increased intestinal proliferation in a feeding-indepen-
dent fashion.
Markus Grompe (Oregon Health and Science University, USA)
discussed ongoing efforts to identify elusive liver stem cells. His
laboratory has produced monoclonal antibodies that might
separate the different stem cell, progenitor, and differentiated
populations in the liver. On the basis of preliminary analysis,
Grompe argued that oval cells may not represent the true stem
cells because they are not clonogenic. However, Grompe has
identified a combination of antibodies that highly enriches for
bipotential clonogenic cells. Interestingly, unlike oval cells, these
cells do not increase in number after acute injury.
Neural Stem Cells and Regeneration
Amputation of the axolotl tail triggers an amazing and coordi-
nated regeneration of the vertebrae, muscles, spinal cord, and
associated peripheral nervous system in which correct embry-
onic spatial coordinates are remembered. The cellular and
molecular control of spinal cord regeneration in the axolotl was
the theme of a talk by Elly Tanaka (Center for Regenerative
Therapies, Germany). Their recent studies of axolotl limb regen-
eration revealed that the blastema—the zone of undifferentiated
progenitors from which all the tissues will reform—was com-
posed of a heterogeneous collection of restricted progenitor
cells rather than just one pluripotent cell type (Kragl et al.,
2009). Tanaka is now searching for the growth factors and the
genes regulating tail regeneration.
Grigori Enikolopov (Cold Spring Harbor Laboratory, USA) dis-
cussed the division and differentiation of adult neural stem cells,
highlighting the observation that neurogenesis decreases with
age. On the basis of cell-labeling studies, Enikolopov presented
the provocative hypothesis that hippocampal quiescent neural
progenitor cells, after activation, underwent several cycles of
asymmetric division to generate transit amplifying neural precur-
sors before finally differentiating into astrocytes. He argued that
the disappearance of stem cells was a direct consequence of
their differentiation to produce new neurons. This then begged
the question of whether the astrocytes that formed from neural
stem cells could be reactivated to generate neurons again.
Magdalena Goetz (Munich University, Germany) also exam-
ined features of neural stem cells, looking for key distinguishing
features. Multipotent cells that could form renewing neuro-
spheres were isolated by their coexpression of glial fibrillary
acidic protein (GFAP) and prominin (CD133), a protein expressed
on the stem cell cilium. Live-cell analysis revealed that in vitro
these astroglial-like cells divided asymmetrically. Goetz also
described reprogramming studies in which astrocytes trans-
duced with single transcription factors were efficiently converted
to neurons within a few days without undergoing further cell
division (Heinrich et al., 2010). This very exciting work implies
that endogenous glial cells may represent a reservoir that could
be tapped to generate new neurons to replace those lost from
trauma or disease.
Arturo Alvarez-Buylla (University of California, San Francisco,
USA) discussed the specification of adult neural stem cells,
concluding that neural stem cells in themouse brain are a region-
ally diverse collection of progenitors with a restricted set of cell
fates (Merkle et al., 2007). His group is now investigating themechanisms that lead to this stem cell heterogeneity, postu-
lating a role for Sonic hedgehog in the specification of cells in
the ventral part of the subventricular zone.Moving Forward
The level of interest in stem cell biology is unprecedented and
there is no evidence that the tsunami of new scientific knowledge
is abating. Search for the words ‘‘stem cell’’ in the publication
title in PubMed and you will retrieve references to nearly 3000
articles published in just the past 12 months. In this meeting
report we have highlighted the increasing suite of clinical
applications of stem cell research that provide tangible evidence
for the translation of science to therapy. We have also noted
presentations that describe direct cellular reprogramming to
convert cells from one cell type to another, demonstrating that
it is possible to bypass a ‘‘dedifferentiation’’ stage, an idea that
was keenly debated in the past. But where will these endeavors
lead? Join us in Toronto in 2011 for the next chapter in this
fascinating tale!REFERENCES
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